Joseph Romanelli - 26 Jan 2026 Form 4 Insider Report for Merck & Co., Inc. (MRK)

Reporting relationship: President, Human Health Int?l
Issuer ticker: MRK
Reported as of: 26 Jan 2026
Net transaction value: +$612,502
SEC form: 4
Accepted by SEC: 28 Jan 2026, 16:14:43 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly E. W. Grez, attorney-in-fact for Joseph Romanelli

Key filing fact

Joseph Romanelli filed Form 4 for Merck & Co., Inc. (MRK) on 28 Jan 2026.

Key facts

This page summarizes Joseph Romanelli's Form 4 filing for Merck & Co., Inc. (MRK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 Jan 2026, 16:14.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: +$612,502.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001938322 Primary reporting owner

Romanelli Joseph

Relationship: President, Human Health Int?l
Address: MERCK & CO., INC., 126 EAST LINCOLN AVENUE, RAHWAY
Signature: /s/ Kelly E. W. Grez, attorney-in-fact for Joseph Romanelli
Signature date: 28 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRK transaction

Common Stock

Award

Transaction value: $612,502
Shares: +5,703
Change %: +25%
Price: $107.40
Shares after: 28,739
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/23. Performance shares were paid out at 94 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2025.

Footnote F2

Holdings include shares acquired in dividend reinvestment transactions.